<unk>  is a combination of a hepatitis C virus NS5A inhibitor and a Hepatitis C virus NS3/4A protease inhibitor that is FDA approved for the treatment of chronic HCV genotype 1 or 4 infection in adults. There is a Black Box Warning for this drug as shown here.  Common adverse reactions include fatigue, headache, and nausea.
Elbasvir / grazoprevir
Sofosbuvir / velpatasvir
Dolutegravir / rilpivirine
Glecaprevir / pibrentasvir
Ledipasvir / sofosbuvir
Ombitasvir / paritaprevir / ritonavir / dasabuvir
Atazanavir and cobicistat
Lopinavir ritonavir